Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Georgina V. Long et al.|The Lancet|2024Cited by 729
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Lisa Hang, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 416
Circulating CD8 <sup>+</sup> mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patientsVictoria M. Vorwald, Richard P. Tobin, Dana M. Davis et al.|Clinical & Translational Immunology|2022Cited by 26
Circulating CD8+ MAIT cells correlate with improved outcomes in anti-PD1 treated melanoma patientsVictoria M. Vorwald, Richard P. Tobin, Dana M. Davis et al.|medRxiv|2020Cited by 1